S Inhibikase Targets A Substantial Market Following Presentation Of Results Presented At The Barcelona Conference
Monday, March 28, 2022 9:26 AM EDT
The upcoming trial results are expected to show an excellent safety profile of the drug and perhaps some biomarkers that translate into efficacy.
In this article: IKT